Dark

Check out our Dark Pool Levels

KALV
KalVista Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive

Jun 10, 2026

27.00USD+0.037%(+0.01)4,272,770

Pre-market

0.00USD-100.000%(-26.99)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsTrends

KALV Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

KALV Specific Mentions

As of Jun 25, 2026 5:16:07 PM EDT (<1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

12 days ago • u/Any_Scientist_7313 • r/biotech_stocks • ntla_deep_dive_why_todays_flawless_phase_3_crispr • C

Thank you for this info, and to OP for highlighting the research published today.
I have been following CRISPR companies off and on for a few years, and also a few of the newer players in HAE therapies (BCRX, KALV, etc). I don’t have any positions in either at the moment, but always looking to learn more and follow the progress.
Anyway, I understand the current SOC is not nearly as effective as NTLA, but what about BCRX Orladeyo? They also published today follow up clinical data that included the following:
"The median (range) adjusted HAE attack rate requiring on-demand treatment decreased from 0.691 attacks/month (0-5.03) during the 12-week standard of care (SOC) period to 0.169 attacks/month (0-1.75) during the 48-week ORLADEYO treatment period."
The 0.169 attacks/month metric in particular would seem to compare favorably to the 0.21 you cited for NTLA, if I am understanding all this correctly.
[Link to PR from BCRX here](https://ir.biocryst.com/news-releases/news-release-details/biocryst-presents-new-clinical-data-and-real-world-evidence)

12 days ago • u/Any_Scientist_7313 • r/biotech_stocks • ntla_deep_dive_why_todays_flawless_phase_3_crispr • C

Thank you for this info, and to OP for highlighting the research published today.
I have been following CRISPR companies off and on for a few years, and also a few of the newer players in HAE therapies (BCRX, KALV, etc). I don’t have any positions in either at the moment, but always looking to learn more and follow the progress.
Anyway, I understand the current SOC is not nearly as effective as NTLA, but what about BCRX Orladeyo? They also published today follow up clinical data that included the following:
"The median (range) adjusted HAE attack rate requiring on-demand treatment decreased from 0.691 attacks/month (0-5.03) during the 12-week standard of care (SOC) period to 0.169 attacks/month (0-1.75) during the 48-week ORLADEYO treatment period."
The 0.169 attacks/month metric in particular would seem to compare favorably to the 0.21 you cited for NTLA, if I am understanding all this correctly.
[Link to PR from BCRX here](https://ir.biocryst.com/news-releases/news-release-details/biocryst-presents-new-clinical-data-and-real-world-evidence)

Share